LeMaitre Vascular (NASDAQ:LMAT) Posts Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) released its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.07), FiscalAI reports. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. During the same quarter last year, the company posted $0.60 EPS. The business’s revenue was up 9.6% compared to the same quarter last year.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q2 organic sales grew 10%, with growth of 12% excluding the temporary catheter recall comparison; operating income rose 26%, EPS increased 23% to $0.74, and operating margin reached a record 29%.
• Artegraft was the fastest-growing product, with sales up 34% and representing 21% of revenue. International sales are expected to reach $11 million in 2026 versus $4 million in 2025, supported by additional country approvals, longer graft sizes, and expanded commercial infrastructure.
• The company reported strong profitability and expansion in Europe, where localized warehouses and sales operations are contributing to significant shipping savings and year-over-year gross-margin gains of roughly 5 to 9 percentage points.
• Full-year revenue guidance was reduced to $276.3 million and organic growth to 11%, reflecting a stronger U.S. dollar, continued Middle East-related export delays, and slower-than-expected cardiac allograft growth because of supply constraints. Operating income guidance was lowered to $76.8 million as the revenue shortfall flows through.
• RestoreFlow and other cardiac allografts remain supply constrained, while the FDA identified additional quality-system observations at the New Jersey facility. The company says production and shipments have not been disrupted, but the QuickStitch project may now require a clinical trial, extending its timeline from quarters to years.

LeMaitre Vascular Price Performance

LMAT stock traded down $24.60 during trading on Wednesday, hitting $81.18. The company had a trading volume of 1,032,720 shares, compared to its average volume of 259,908. The company has a fifty day moving average price of $97.41 and a two-hundred day moving average price of $100.04. LeMaitre Vascular has a fifty-two week low of $79.39 and a fifty-two week high of $118.01. The company has a market cap of $1.85 billion, a P/E ratio of 29.93, a P/E/G ratio of 2.88 and a beta of 0.53. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bridget A. Ross sold 5,044 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the sale, the director owned 3,942 shares in the company, valued at $437,956.20. The trade was a 56.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 54,453 shares of company stock worth $5,906,174 in the last quarter. 7.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LMAT. Illinois Municipal Retirement Fund boosted its stake in LeMaitre Vascular by 1.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 123 shares during the last quarter. NewEdge Advisors LLC increased its stake in LeMaitre Vascular by 4.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares in the last quarter. Federated Hermes Inc. raised its holdings in LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after purchasing an additional 155 shares during the period. Equitable Holdings Inc. boosted its position in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier’s stock worth $1,173,000 after purchasing an additional 205 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of LeMaitre Vascular by 1.7% during the second quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier’s stock worth $1,555,000 after purchasing an additional 316 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analysts Set New Price Targets

LMAT has been the subject of several research reports. Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a research report on Wednesday. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Finally, Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular News Summary

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, while earnings per share rose to $0.74 from $0.60 a year earlier. The company also maintained strong profitability, with a 24.35% net margin. LeMaitre Q2 2026 Financial Results
• Positive Sentiment: LeMaitre declared a quarterly dividend of $0.25 per share, payable September 3 to shareholders of record August 20. The dividend represents an annualized yield of approximately 1.1%.
• Neutral Sentiment: Wells Fargo lowered its price target from $104 to $94 and maintained an “equal weight” rating, implying potential upside from the recent trading level but signaling a more cautious valuation view. Benzinga
• Negative Sentiment: Q2 EPS of $0.74 missed the $0.81 consensus estimate, while revenue of $70.38 million fell short of the $71.47 million forecast. LeMaitre Q2 Earnings and Revenues Lag Estimates
• Negative Sentiment: Management’s updated third-quarter guidance is below consensus: EPS of $0.66–$0.71 versus $0.73 expected and revenue of $66.3–$68.3 million versus $69.0 million expected.
• Negative Sentiment: Full-year 2026 guidance was also reduced to EPS of $2.84–$2.94 and revenue of $274.3–$278.3 million, below consensus estimates of $3.00 and $279.9 million, respectively.
• Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” adding to the cautious investor reaction. Finviz

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.